Active Ingredient History

NOW
  • Now
Etifoxine is an anxiolytic and anticonvulsant drug developed by Hoechst in the 1960s. It is sold in approximately 40 countries for anxiety disorders, without the sedation and ataxia associated with benzodiazepine drugs. It has similar anxiolytic effects to benzodiazepine drugs, but is structurally distinct, although it has structural elements in common with them. Studies suggest is as effective as lorazepam as an anxiolytic, but has fewer side effects. Etifoxine is not approved by the U.S. Food and Drug Administration. The European Medicines Agency (EMA) started a review procedure regarding the effectiveness and safety of etifoxine following a French study that compares etifoxine's effectiveness to placebo. In January 2022, the EMA "finalized its review of Stresam and concluded that the medicine can continue to be used for the treatment of anxiety disorders, but it must not be used in patients who previously had severe skin reactions or severe liver problems after taking etifoxine."   Wikipedia

  • SMILES: CCNC1=Nc2ccc(Cl)cc2C(C)(O1)c3ccccc3
  • InChIKey: IBYCYJFUEJQSMK-UHFFFAOYSA-N
  • Mol. Mass: 300.79
  • ALogP: 4.23
  • ChEMBL Molecule:
More Chemistry
2-ethylamino-6-chloro-4-methyl-4-phenyl-4h-3,1-benzoxazine | 36-801 | etafenoxine | etafenoxine hydrochloride | etifoxin | etifoxine | etifoxine hydrochloride | hoe 36801 | hoe-36801 | stresam

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue